Lpa1 antagonists for treating interstitial lung disease
AssigneeBristol-Myers Squibb Company
InventorsAryeh FISCHER, Steven GREENBERG, Ashfaq A. PARKAR, Daniel A. TATOSIAN, Giridhar S. TIRUCHERAI, Shiwei TAO
Life of this patent
Estimating the term…
Abstract
This disclosure relates to methods of treating interstitial lung disease by administering an LPA1 antagonist to the subject at one or more daily dosages lower than the standard daily dosage during a dose titration period of treatment then increasing the dosage to the standard daily dosage of the LPA1 antagonist.
Claims39
A method of treating interstitial lung disease in a subject in need thereof, the method comprising administering an LPA1 antagonist to the subject at one or more daily dosages lower than the standard daily dosage during a dose titration period of treatment then increasing the daily dosage to the standard daily dosage of the LPA1 antagonist.
-6. (canceled)
-12. (canceled)
-17. (canceled)
-23. (canceled)
A method of treating interstitial lung disease in a subject in need thereof, the method comprising administering an LPA1 antagonist to the subject at a daily dosage lower than the standard daily dosage during an initial period of treatment, followed by administering the dosage at a daily dosage higher than the initial period but lower than the standard daily dosage for a second period of treatment, then increasing the dosage to the standard daily dosage of the LPA1 antagonist.
-29. (canceled)
-35. (canceled)
(canceled)
-44. (canceled)
-57. (canceled)
In a method of treating a subject with an LPA1 antagonist for treating interstitial lung disease, the improvement comprising:
- reducing the incidence of cardiovascular adverse events in the subject receiving the LPA1 antagonist by use of an initial dose escalation regimen comprising administering the LPA1 antagonist to the subject at a daily dosage lower than the standard daily dosage during an initial period of treatment then increasing the dosage to the standard daily dosage of the LPA1 antagonist.
-65. (canceled)
Dependencies are inferred from the claim text.